Fill-Finish, Decontamination, and Medical Device Assembly

CPHI Milan 2026 Fill-Finish, Decontamination, and Medical Device Assembly

2026-09-25 Source: Press release IMA 2 min Reading Time

Related Vendors

IMA Industria Macchine Automatiche SpA

DÜPERTHAL Sicherheitstechnik GmbH & Co. KG

Glatt Ingenieurtechnik GmbH

Italvacuum, Srl

Magnetic levitation moves ready-to-use components without mechanical contact during transport. The approach reduces friction and the associated risk of particle generation. At CPHI Milan, Ima will present the Tile-X solution for aseptic fill-finish applications with a decontamination tunnel.

The VPHP Bioindicator is based on spores of Geobacillus stearothermophilus ATCC 12980 and uses packaging permeable to VPHP.(Source: Ima) — The VPHP Bioindicator is based on spores of Geobacillus stearothermophilus ATCC 12980 and uses packaging permeable to VPHP.
(Source: Ima)

At CPHI Milan, the Pharmaceutical and Med-Tech divisions of Ima Group will present selected technologies for pharmaceutical processing, aseptic fill-finish, isolator decontamination, and medical device assembly. The focus will be on the Tile-X line with Nebula, the VPHP Bioindicator, as well as the X Pen Lab for clinical trials and small-scale production.

Tile-X with Nebula for Aseptic Fill-Finish

Following its world premiere at Interpack 2026, Ima Life will present the Tile-X line at CPHI Milan for the first time in Italy. The system is designed for the aseptic processing of ready-to-use (RTU) components and is intended for applications involving high-value pharmaceutical products, including biopharmaceuticals and advanced therapy medicinal products (ATMPs), with a focus on cell and gene therapies.

Gallery

The Tile-X is designed for the aseptic processing of RTU components with the integrated decontamination tunnel Nebula.(Source: Ima)

The X Pen Lab is a semi-automatic system for the final assembly of pens and autoinjectors in clinical-trial applications, early-stage development and small-scale production.(Source: Ima)

Tile-X uses magnetic levitation technology for the transport of components. The contactless handling concept reduces mechanical friction and the associated risk of particle generation. Nebula is a fast, integrated decontamination tunnel for RTUs.

VPHP Bioindicator

At the Isotech Lab – a corner devoted to the Isolator Research & Development Laboratory – Ima Life will present the VPHP Bioindicator. The biological indicator has been developed for the validation and monitoring of vaporized hydrogen peroxide (VPHP) bio-decontamination cycles in isolators.

The indicator is based on spores of Geobacillus stearothermophilus ATCC 12980 and uses packaging that is permeable to VPHP. It is intended for use in cycle development, performance qualification, re-qualification, and ongoing contamination-control strategies.

X Pen Lab for Clinical Trials and Small-Scale Production

Ima Med-Tech will display the X Pen Lab, a semi-automatic system for the final assembly of pens and autoinjectors. The equipment is designed for clinical-trial applications, early-stage development, and small-scale production. The system performs press-fit operations with monitored force and distance measurement. Manual loading and unloading support the processing of different variants within one platform. The solution is part of the X Pen series, which is based on a linear magnetic transport system (LMTS).

Depending on the configuration, the X Pen platform can achieve production speeds between 40 and 160 ppm. Available options include vision inspection, handling of prefilled syringes without glass-to-glass contact, force- and distance-controlled assembly, priming, and labeling.

Technologies Across the Pharmaceutical Process Chain

Ima Pharma comprises several specialized divisions covering solid-dose processing (Ima Active), aseptic processing and freeze drying solutions (Ima Life), secondary packaging (Ima Safe), end-of-line systems (Ima BFB) and medical device assembly (Ima Med-Tech). Its portfolio includes equipment and complete lines for pharmaceutical, nutraceutical and medical products. Alongside machinery, Ima also develops solutions for digitalisation, sustainability and service support. The technologies presented at CPHI Milan are intended to address selected process requirements ranging from component handling and isolator decontamination to the assembly of drug-delivery devices.

CPHI Milan 2026: Booth 9C2

(ID:50963678)

Consent to the use of data for promotional purposes

I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here

Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.

Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.

In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.

Right of revocation

I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.